TY - JOUR
T1 - Polyethylenimine-Dermatan Sulfate Complex, a Bioactive Biomaterial with Unique Toxicity to CD146-Positive Cancer Cells
AU - Kim, Bieong Kil
AU - Kim, Dongkyu
AU - Kwak, Gijung
AU - Yhee, Ji Young
AU - Kwon, Ick Chan
AU - Kim, Sun Hwa
AU - Yeo, Yoon
N1 - Publisher Copyright:
© 2017 American Chemical Society.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/6/12
Y1 - 2017/6/12
N2 - We report unique bioactivity of a polycation-polyanion complex with potential utility for cancer therapy. A complex of disulfide-cross-linked polyethylenimine (CLPEI), a polycation used for gene complexation, and dermatan sulfate (DS), an anionic polysaccharide to shield excessive cationic charge of the former, has toxicity to a specific group of cancer cell lines, including B16-F10 murine melanoma, A375SM human melanoma, and PC-3 human prostate cancer cells. These CLPEI-DS-sensitive cells express CD146, which binds to the complex via interaction with DS. There is a positive correlation between toxicity and intracellular level of CLPEI, indicating that the CLPEI-DS-sensitivity is attributable to the increased cellular uptake of CLPEI mediated by the DS-CD146 interactions. In vitro studies show that CLPEI-DS complex causes G0/G1 phase arrest and apoptotic cell death. In syngeneic and allograft models of B16-F10 melanoma, CLPEI-DS complex administered with a subtoxic level of doxorubicin potentiates the chemotherapeutic effect of the drug by loosening tumor tissues. Given the unique toxicity, CLPEI-DS complex may be a useful carrier of gene or chemotherapeutics for the therapy of CD146-positive cancers.
AB - We report unique bioactivity of a polycation-polyanion complex with potential utility for cancer therapy. A complex of disulfide-cross-linked polyethylenimine (CLPEI), a polycation used for gene complexation, and dermatan sulfate (DS), an anionic polysaccharide to shield excessive cationic charge of the former, has toxicity to a specific group of cancer cell lines, including B16-F10 murine melanoma, A375SM human melanoma, and PC-3 human prostate cancer cells. These CLPEI-DS-sensitive cells express CD146, which binds to the complex via interaction with DS. There is a positive correlation between toxicity and intracellular level of CLPEI, indicating that the CLPEI-DS-sensitivity is attributable to the increased cellular uptake of CLPEI mediated by the DS-CD146 interactions. In vitro studies show that CLPEI-DS complex causes G0/G1 phase arrest and apoptotic cell death. In syngeneic and allograft models of B16-F10 melanoma, CLPEI-DS complex administered with a subtoxic level of doxorubicin potentiates the chemotherapeutic effect of the drug by loosening tumor tissues. Given the unique toxicity, CLPEI-DS complex may be a useful carrier of gene or chemotherapeutics for the therapy of CD146-positive cancers.
KW - CD146
KW - bioactive biomaterials
KW - dermatan sulfate
KW - melanoma
KW - polyethylenimine
UR - http://www.scopus.com/inward/record.url?scp=85020703733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020703733&partnerID=8YFLogxK
U2 - 10.1021/acsbiomaterials.7b00207
DO - 10.1021/acsbiomaterials.7b00207
M3 - Article
AN - SCOPUS:85020703733
VL - 3
SP - 990
EP - 999
JO - ACS Biomaterials Science and Engineering
JF - ACS Biomaterials Science and Engineering
SN - 2373-9878
IS - 6
ER -